NL-OMON51226尚未招募2 期
A multiple dosing study to demonstrate the safety, tolerability, pharmacokinetics and efficacy potential of intravenously administered ANXV (a recombinant human Annexin A5) in patients with confirmed moderate to severe COVID-19; The CO-ANNEXIN Study. - The CO-ANNEXIN STUDY
Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Patients hospitalized for laboratory documented SARS-CoV2 infection
- •(qRT-PCR).
- •2. Males between 18 and 75 years or Females of non-reproductive age or
- •capacity, i.e post-menopausal or sterile, and between 18 and 75 years.
- •3. Signed informed consent by patient
- •4. Hospitalized with a resting oxygen saturation on room air of <92 %, AND
- •receiving high flow nasal oxygen.
- •5. Elevated LDH (>350U/L, n=97-247 U/l)
- •6. Mentally Competent
排除标准
- •1. Subject requiring mechanical ventilation/ extracorporeal membrane
- •oxygenation and in-tubated for mechanical ventilation.
- •2. Severe COPD, defined by continuous use of long-acting bronchodilators or
- •inhaled/oral corticosteroids for > 2 months in the home situation.
- •3. Subject with severe renal impairment (eGFR < 30 ml/min)
- •4. Subjects on chronic dialysis.
- •5. Subject with an active malignancy within the last three months, and/or a
- •risk of mortality >50% within 6 months.
- •6. Bleeding Risk:
- •a. Clinical: Active bleeding; head trauma, intracranial surgery or stroke
- •within 3 months; history of intracerebral arteriovenous malformation, cerebral
- •aneurysm or mass lesions of the central nervous system; cerebral haemorrhage;
- •history of a bleeding diatheses; gastrointestinal bleeding within 6 weeks;
- •presence of an epidural or spinal catheter; contraindication for IV therapeutic
- •b. Laboratory: Platelet count <50 x109/L, INR >3.0 or baseline aPTT >=45 seconds
- •prior to enrolment.
- •7. Use of any of the following treatments: UFH to treat a thrombotic event
- •within 12 hours before enrolment; thrombolytic therapy within 3 previous days;
- •8. Confirmed antiphospholipid syndrome, systemic lupus erythematosus and other
- •auto-immune diseases (at discretion of PI)
- •9. Confirmed thalassemias (e.g sickle cell disease)
- •10. Cardiopulmonary resuscitation in previous 7 days.
- •11. Liver failure defined as Child-Pugh Score Class C.
- •12. Abnormal liver function (AST >5xULN, ALT >5xULN)
- •13. Life expectancy of <24 hours
- •14. Treating physician refusal.
研究者
相似试验
进行中（未招募）
1 期
The CO-ANNEXIN study; assessing the efficacy and safety of ANXV (recombinant Annexin A5) in moderate tosevere COVID-19.moderate to severe COVID-19 pneumoniaEUCTR2021-002200-12-NLMUMC AZm12
已完成
不适用
A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Subjects with Hepatitis C InfectioHepatitis CNL-OMON41065Merck Sharp & Dohme (MSD)5
已完成
1 期
A single centre, double blind, randomised, parallel group, single and multiple dose, safety and tolerability, pharmacokinetic study of R131-2 vaginal soft gel capsule in healthy women volunteersCervical neoplasiaCondyloma acuminatumInfection - Sexually transmitted infectionsACTRN12621001487808Zenith Technology Corporation Limited12
已完成
1 期
A multiple dose study to investigate the safety of ACH-0144471 in healthy volunteersComplement-mediated diseases.Inflammatory and Immune System - Autoimmune diseasesACTRN12616000568415Achillion Pharmaceuticals, Inc.46
已完成
不适用
Study to investigate the effects and safety of ENX-102 in healthy volunteers.ENX-102 is a new research drug that is being developed for the treatment of neuropsychiatric disorders.Nervous System DiseasesISRCTN61386931Engrail Therapeutics, Inc40